Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.

@inproceedings{Schindler2014CorrelationOA,
  title={Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.},
  author={Katja Schindler and Kaan Harmankaya and Deborah Kuk and Johanna Mangana and Olivier Michielin and Christoph Hoeller and Reinhard Dummer and Hubert Pehamberger and Jedd D. Wolchok and Michael A Postow},
  year={2014}
}
9096 Background: Ipilimumab (ipi) has shown significant improvements in overall survival (OS) for patients (pts) with advanced melanoma in randomized phase III trials. Easily obtainable pre- or on-treatment biomarkers would be helpful to optimize this therapy. In a prior analysis, IL-17 levels correlated with immune-related adverse events (irAEs), and IL-17 and eosinophils are immunologically related. In one prior single institution study of 73 ipi-treated pts, an increase in absolute… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Similar Papers